Critical Survey: Adynxx (OTCMKTS:ADYX) and IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM) and Adynxx (OTCMKTS:ADYX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Insider and Institutional Ownership

0.6% of IceCure Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 17.4% of Adynxx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares IceCure Medical and Adynxx’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.34 million	8.74	-$14.65 million	($0.33)	-1.94
Adynxx	N/A	N/A	N/A	N/A	N/A

Adynxx has lower revenue, but higher earnings than IceCure Medical.

Risk & Volatility

IceCure Medical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Adynxx has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for IceCure Medical and Adynxx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	0	0	2	0	3.00
Adynxx	0	0	0	0	N/A

IceCure Medical presently has a consensus target price of $2.70, indicating a potential upside of 322.54%.

Profitability

This table compares IceCure Medical and Adynxx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-410.22%	-111.27%	-81.41%
Adynxx	N/A	N/A	N/A

Summary

Adynxx beats IceCure Medical on 5 of the 8 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.